Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
fabp4 inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "fabp4 inhibitor" in MCE Product Catalog:
29
29 Publications Verification
Target:
Research Areas:
BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
29
29 Publications Verification
Target:
Research Areas:
BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
4
4 Cited Publications
Cat. No.: HY-N2445
CAS No.: 37308-75-1
Cat. No.: HY-161702
CAS No.: 1433901-75-7
Target:
Research Areas:
RO6806051 is a selectivity FABP4 and FABP5 inhibitor with human FABP4 Ki values of 0.011 μM and 0.23 μM, and human FABP5 Ki values of 0.086 μM and 1.17 μM. RO6806051 can be used for the research of inflammation-related diseases .
Cat. No.: HY-163032
CAS No.: 3053862-47-5
Target:
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 Ki = 25 ± 3 a nM, FABP3 Ki = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .
Cat. No.: HY-W012865
CAS No.: 80-69-3
Research Areas:
Tartronic acid, a dicarboxylic acid derive, is an inhibitor of the transformation of carbohydrates into fat under fat-deficient diet conditions. Tartronic acid promotes 3T3-L1 adipocyte differentiation by increasing the protein expression of FABP-4, PPARγ and SREBP-1. Tartronic acid promotes de novo lipogenesis and inhibits CPT-1β by upregulating acetyl-CoA and malonyl-CoA. Tartronic acid promotes weight gain and induces adipocyte hypertrophy in epididymal white adipose tissue and lipid accumulation in the livers of high-fat diet induced obese mice. Tartronic acid can be used for lipid metabolic disease research .
Cat. No.: HY-161904
CAS No.: 2378625-66-0
Research Areas:
CDYL-IN-1 is a selective small-molecule inhibitor of CDYL with a KD value of 0.5 μM. CDYL-IN-1 improves renal dysfunction, pathological damage and renal tubular pyroptosis, inhibits FABP4-mediated ROS production, and alleviates renal tubular epithelial cell injury. CDYL-IN-1 is applicable to the research of acute kidney injury .
Cat. No.: HY-160457
CAS No.: 2862791-11-3
Target:
Research Areas:
FABP4/5-IN-5 (compound D9) is a potent inhibitor of FABP4 and FABP5,? with the IC50s of 4.68 μM and 10.72 μM, respectively.FABP4/5-IN-5 plays an important role in metabolism disorder like diabetes mellitus .
Cat. No.: HY-149953
CAS No.: 2983117-36-6
Target:
Research Areas:
FABP4-IN-2 (Compd 10g) is a selective and orally active FABP4 inhibitor with the Ki values of 0.51 μM for FABP4, 33.01 μM for FABP3. FABP4-IN-2 can be used in the research of inflammation-related diseases .
Cat. No.: HY-160456
CAS No.: 2862795-48-8
Target:
Research Areas:
FABP4/5-IN-4 (compound E1) is a potent inhibitor of FABP4 and FABP5, with the IC50s of 3.78 μM and 5.72 μM, respectively. FABP4/5-IN-4 plays an important role in metabolism disorder like diabetes mellitus .
Cat. No.: HY-178471
CAS No.: 2975215-64-4
Target:
Research Areas:
FABP4/5-IN-6 is an orally active, potent FABP4/5 inhibitor (Ki = 0.41/2.53 μM), showing low selectivity over FABP3 (Ki = 59.72 μM). FABP4/5-IN-6 inhibits the secretion of MCP-1 and IL-6 in Lipopolysaccharides (HY-D1056) (LPS)-induced THP-1 macrophage. FABP4/5-IN-6 exhibits significant anti-inflammatory effects and attenuates LPS-induced liver injury. FABP4/5-IN-6 has low hERG inhibition (LD50 > 2000 mg/kg). FABP4/5-IN-6 can be used for the study of Inflammation-related diseases .
Cat. No.: HY-161892
Target:
Research Areas:
FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .
Cat. No.: HY-101903AR
CAS No.: 2802523-05-1
Target:
Research Areas:
BMS-309403 (sodium) (Standard) is the analytical standard of BMS-309403 (sodium). This product is intended for research and analytical applications. BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
Cat. No.: HY-101903R
CAS No.: 300657-03-8
Target:
Research Areas:
BMS-309403 (Standard) is the analytical standard of BMS-309403. This product is intended for research and analytical applications. BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
Cat. No.: HY-W011214
CAS No.: 50257-40-4
Target:
Research Areas:
FABP4-IN-6 is a FABP4 inhibitor with an IC50 of 16.8 μM. FABP4-IN-6 can be used in the research of diabetes and atherosclerosis .
Cat. No.: HY-183836
CAS No.: 1227413-92-4
Target:
Research Areas:
FABP4/5-IN-7 is a dual FABP4/FABP5 inhibitor, with an IC50 of 0.8 μM and a Kd of 0.01 μM for FABP4, and an IC50 of 1.4 μM for FABP5. FABP4/5-IN-7 inhibits lipolysis in adipocytes. FABP4/5-IN-7 inhibits MCP-1 release in macrophages. FABP4/5-IN-7 improves dyslipidemia in diet-induced obese mice. FABP4/5-IN-7 can be used in studies related to dyslipidemia .
Cat. No.: HY-P10873
Research Areas:
Cat. No.: HY-187805
CAS No.: 1022924-71-5
CID-145925339 is a binder of fatty acid-binding protein 4 (FABP4). CID-145925339 binds to the active site of FABP4 and forms stable interactions with key amino acid residues of this protein. Computational prediction shows that CID-145925339 inhibits FABP4, which is overexpressed in colorectal adenocarcinoma, with favorable druglike properties and no obvious toxicity. CID-145925339 can be used in studies related to colorectal adenocarcinoma .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
